Cabot Corporation announced the availability to produce in Asia Pacific its circular reinforcing carbons powered by its EVOLVE Sustainable Solutions technology platform. As such, Cabot's manufacturing ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

People who order low-cost versions of the wildly popular weight-loss drugs Wegovy and Zepbound from so-called compounding pharmacies might soon see disruptions in their medication. The U.S. Food and ...

On Thursday, Hims & Hers Health Inc. (NYSE: HIMS) announced Thursday an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ...

Novo Nordisk is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company's patents, and is seeking to recover damages. The move escalates the ...

A high-profile fight in the world of compounded drugs looks like it has been resolved, with telehealth firm Hims & Hers (HIMS) backing off a plan to offer a knockoff Wegovy pill for as little as $49 ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Novo Nordisk NOVO.B-0.29%decrease; red down pointing triangle accused Hims & Hers of “illegal mass compounding” after the telehealth platform said it would offer a cheaper, compounded version of the ...

The U.S. Food and Drug Administration said on Friday it would take action against telehealth provider Hims & Hers for its $49 weight-loss pill, including restricting access to the drug's ingredients ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Hims & Hers (HIMS) shares dropped 16% after-hours as FDA plans to restrict compounded GLP-1 ingredients and HHS referred Hims to DOJ. Hims projected $725M in weight-loss revenue for 2025 from total ...

Share on Pinterest Hims & Hers has withdrawn its low cost compounded weight loss pill after pressure from top U.S. health officials and a major lawsuit. Image courtesy of Novo Nordisk Hims & Hers ...